NASDAQ: YTENYield10 Bioscience Inc Stock
$0.26-0.01 (-3.7%)
Updated Apr 19, 2024
YTEN Price
$0.26
Fair Value Price
-$0.29
Market Cap
$3.93M
52 Week Low
$0.18
52 Week High
$3.29
P/E
-0.14x
P/B
-1.58x
P/S
31.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$60.00k
Earnings
-$14.46M
Gross Margin
100%
Operating Margin
-24,091.67%
Profit Margin
-24,091.7%
Debt to Equity
-2.57
Operating Cash Flow
-$10M
Beta
0.9
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
YTEN Overview
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
Zen Score
–
Industry Average (31)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how YTEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
YTEN ($0.26) is overvalued by 186.62% relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
YTEN ($0.26) is not significantly undervalued (186.62%) relative to our estimate of its Fair Value price of -$0.29 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
YTEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more YTEN due diligence checks available for Premium users.
Be the first to know about important YTEN news, forecast changes, insider trades & much more!
YTEN News
Valuation
YTEN fair value
Fair Value of YTEN stock based on Discounted Cash Flow (DCF)
Price
$0.26
Fair Value
-$0.29
Undervalued by
188.32%
YTEN ($0.26) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
YTEN ($0.26) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
YTEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
YTEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
26.55x
Market
40.51x
YTEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.58x
Industry
1.37x
YTEN's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
YTEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
YTEN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.9M
Liabilities
$6.4M
Debt to equity
-2.57
YTEN's short-term liabilities ($4.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
YTEN's long-term liabilities ($1.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
YTEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
YTEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.7M
Investing
-$20.0k
Financing
$0.0
YTEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
YTEN vs Agricultural Input Stocks
Yield10 Bioscience Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.